Short interest for Heron Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Heron Therapeutics's stock. Short interest data is updated every two weeks.

Heron Therapeutics Stock (NASDAQ:HRTX), Short Interest Report

Heron Therapeutics

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Movers

News

Intraday Update

Markets

ABEO

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HIBB

HRTX

HSTM

JAGX

JBLU

KULR

LICN

MESO

MLEC

MSCI

OPRT

PALI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

TTOO

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

BGNE

CRML

MARA

RGEN

SMCI

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday

Analyst Color

Biotech

Earnings

Equities

Guidance

Health Care

Price Target

Analyst Ratings

Trading Ideas

General

Heron Therapeutics&#39; Q4 2023 results: Beat EPS consensus at $(0.07), $34.23 million sales, up 14% Y/Y. Strong momentum in acute and oncology care franchises. Fiscal year 2024 guidance: $138 million-$158 million revenue, with positive adjusted EBITDA.

Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?

Heron Therapeutics Inc

Shares of Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/04/38365860/nucor-shares-fall-after-worse-than-expected-q1-results">quarterly financial results</a>.
Nucor reported quarterly earnings of $3.46 per share which missed the analyst consensus estimate of $3.65. Quarterly sales came in at $8.14 billion, missing the analyst consensus estimate of $8.26 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Nucor shares tumbled 6.5% to $179.20 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares jumped 100% to $0.2419 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere&#8217;s operation in Dubuque, Iowa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares climbed 50.4% to $0.0689 after falling 10% on Monday.</li>
<li>Oportun Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) gained 46% to $3.29 after the company announced preliminary first-quarter total revenue above estimates.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares climbed 44.3% to $7.12 after the company entered a collaboration with Strand Life Sciences.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) gained 27% to $0.5683 after the company announced it delivered on an immediate basis, a power cell battery deployment order for AI-enabled drone and advanced air mobility missions in Ukraine.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) climbed 20% to $5.22.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 19.5% to $1.5307 after declining 3% on Monday.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) gained 18.7% to $9.49.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) rose 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 17.4% to $1.3499.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) rose 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) gained 15.5% to $0.9295.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) climbed 15.2% to $2.20.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares gained 15% to $0.2244 after the company announced new preclinical data will be presented at the American Society of Gene and Cell Therapy meeting.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) jumped 14.4% to $0.8603.</li>
<li>9F Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFU#NASDAQ">JFU</a>) rose 14.3% to $3.29.</li>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) gained 14% to $1.05. The company executives announced intentions to purchase at least $2 million of the company's common stock.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) jumped 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) climbed 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 9.4% to $6.05.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) rose 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) jumped 8.8% to $10.15.</li>
<li>HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) surged 7.4% to $25.91 following upbeat quarterly results.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 7% to $0.55 following upbeat quarterly results.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) gained 6.2% to $62.20.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) fell 48.4% to $3.7950 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares fell 44.6% to $0.0699. Greenwave Technology Solutions disclosed that it further strengthened its balance sheet by approximately $12 million.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) fell 44.4% to $0.5450.</li>
<li>Tungray Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares declined 34.2% to $4.87 after gaining 24% on Monday.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) fell 26.3% to $0.5091.</li>
<li>Moolec Science SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) fell 24.3% to $1.87. On April 22, Moolec Science said it received approval for its plant-grown animal proteins.</li>
<li>YY Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) fell 22.4% to $2.25 after tumbling over 27% on Monday. The company, last week, priced its IPO at $4 per share.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) dipped 19.7% to $2.0899.</li>
<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) declined 18.8% to $6.44.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) dipped 18% to $0.2369. SuperCom recently reported better-than-expected quarterly results.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) declined 16.2% to $6.29 after the company reported first-quarter financial results and issued worse-than-expected Q2 and FY24 Revenue outlook.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) declined 13% to $448.01 following first-quarter financial results.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.6% to $42.78 after the company reported a first-quarter earnings miss and cut its FY24 outlook.</li>
<li>Simpson Manufacturing Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) dipped 11.7% to $163.40 following weak quarterly earnings.</li>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares fell 11.2% to $0.1598 after the company filed for a mixed shelf offering of up to $75 million.</li>
<li>Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) tumbled 11.1% to $14.60 after the company reported worse-than-expected first-quarter results and reiterated FY24 guidance.</li>
<li>T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) declined 10.4% to $2.83 after gaining around 7% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) shares fell 10.1% to $7.13 after the company issued its production and sales performance metrics for the nine months ended 31 March, 2024.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) fell 9.3% to $0.3530 after dipping around 14% on Monday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) dipped 7.8% to $19.22 after the company&#8217;s reported worse-than-expected first-quarter financial results.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 7.1% to $0.77. Phio Pharmaceuticals shares jumped around 33% on Monday after the company announced that its intratumoral injection of murine PH-762 inhibited tumor growth in murine tumor models and may generate memory-specific T cells.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) shares fell 4.1% to $28.34 after the company reported mixed first-quarter financial results and issued second-quarter guidance below estimates.</li>
</ul>
Read More: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38379861/bitcoin-surpasses-66-000-akash-network-core-among-top-gainers">Bitcoin Surpasses $66,000; Akash Network, Core Among Top Gainers</a>

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday.
Shares of HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) rose sharply during Tuesday's session following upbeat <a href="https://www.benzinga.com/quote/HSTM/earnings">quarterly results</a>.
HealthStream posted first-quarter GAAP earnings of 17 cents per share, beating market estimates of 11 cents per share. The company's quarterly sales came in at $72.760 million versus expectations of $71.883 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
HealthStream shares jumped 7.4% to $25.91 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares gained 29% to $2.03.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) shares climbed 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares jumped 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) rose 15.5% to $0.9295.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) climbed 14.2% to $1.3150.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) gained 14.4% to $0.8603.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) rose 14.2% to $10.30. Critical Metals named Tony Sage as Chief Executive Officer.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) surged 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) shares jumped 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) gained 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) rose 10.3% to $22.42.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) climbed 9.6% to $172.59 as life sciences stocks gained following strong earnings from Danaher.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) surged 9.4% to $6.05.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rose 9.2% to $783.26.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) climbed 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 8.8% to $10.15.</li>
<li>Lifezone Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZM#NYSE">LZM</a>) gained 8.4% to $7.26.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) rose 8.1% to $10.86.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) surged 8.1% to $19.00.</li>
<li>BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) rose 7.4% to $140.70 after the European Commission approved Tislelizumab for non-small cell lung cancer across three indications, including first- and second-line use.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose 7% to $252.49 following better-than-expected first-quarter financial results.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) gained 6.6% to $172.15.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares jumped 6.2% to $62.20.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/04/38376714/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 3% Dividend Yields</a>

WIIM

Heron Therapeutics shares are trading higher after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.

Capital One analyst Tim Chiang initiates coverage on Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Overweight rating and announces Price Target of $6.

Initiation

Capital One Initiates Coverage On Heron Therapeutics with Overweight Rating, Announces Price Target of $6

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $5 price target.

Reiteration

Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target

Tuesday,&nbsp;Heron Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported a fourth-quarter 2023 EPS of $(0.07), beating the consensus of $(0.16).
Sales increased 14% Y/Y to $34.23 million, beating the consensus of $30.98 million due to stronger upticks in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37633659/heron-therapeutics-announces-fourth-quarter-and-full-year-2023-financial-results-and-highlights-re" rel="noreferrer noopener">Zynrelef, Cinvanti, and Sustol</a>.
&#8220;In the fourth quarter of 2023, Heron saw continued positive momentum and an increased sales trajectory in both our acute care and oncology care franchises, illustrating how the strategic decisions made over the past year have positioned the Company for long-term success and profitability,&#8221; said Craig Collard, Chief Executive Officer of Heron.&nbsp;
Acute Care Franchise sales increased from $3.9 million to $6.1 million in the fourth quarter of 2023.
Oncology Care Franchise sales reached $28.1 million versus $26.1 million a year ago.&nbsp;
Guidance:&nbsp;Heron Therapeutics expects fiscal year 2024 product revenues of $138 million-$158 million, with adjusted EBITDA of $(22.0) million-$3.0 million.
The strong finish to 2023 is expected to bolster confidence in the company&#8217;s ability to achieve its revenue target of $138 million to $158 million and its target to achieve positive adjusted EBITDA.
Needham&nbsp;maintains its Buy rating on the company&#8217;s stock and revises the price target upward from $4 to $5 to reflect adjustments in financial models and recent sales trends.&nbsp;
The analysts anticipate that it may take several quarters of improved sales performance to demonstrate significant progress toward achieving the envisioned level of profitability.
Price Action: HRTX shares are up 30.1% at $3.07 on the last check Wednesday.

<h3>Gainers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) shares rose 35.4% to $3.19 during Wednesday's regular session. The market value of their outstanding shares is at $479.4 million. The company's, Q4 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock rose 34.56% to $0.52. The market value of their outstanding shares is at $23.8 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 34.32% to $0.52. The company's market cap stands at $27.2 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares moved upwards by 33.01% to $0.11. The market value of their outstanding shares is at $4.3 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) shares increased by 27.9% to $5.73. The company's market cap stands at $256.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares increased by 26.36% to $5.8. The company's market cap stands at $453.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares fell 22.6% to $26.24 during Wednesday's regular session. The market value of their outstanding shares is at $31.6 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares fell 22.0% to $1.13. The company's market cap stands at $2.7 million. The company's, Q4 earnings came out yesterday. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock declined by 21.49% to $0.8. The market value of their outstanding shares is at $92.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock fell 20.4% to $6.05. The company's market cap stands at $118.2 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) stock fell 18.28% to $14.18. The company's market cap stands at $2.2 billion. The company's, Q4 earnings came out 4 days ago. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) stock declined by 16.28% to $0.36. The market value of their outstanding shares is at $17.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANNX

Envoy Medical, Inc. - Class A Common Stock

COCH

CRDF

Kintara Therapeutics, Inc. - Common Stock

KTRA

MEDS

NCNA

NMRA

PIII

TCON

TNON

12 Health Care Stocks Moving In Wednesday's Intraday Session

Heron therapeutics shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $4 to $5.

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and raises the price target from $4 to $5.

Needham Maintains Buy on Heron Therapeutics, Raises Price Target to $5

Heron therapeutics shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 revenue guidance.

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Heron Therapeutics beat estimated earnings by 56.00000000000001%, reporting an EPS of $-0.07 versus an estimate of $-0.16.
Revenue was up $4.21 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.12 which was followed by a 59.0% increase in the share price the next day.
Here's a look at Heron Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.23</td>
<td>-0.20</td>
<td>-0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.35</td>
<td>-0.27</td>
<td>-0.17</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>32.75M</td>
<td>31.70M</td>
<td>29.69M</td>
<td>26.90M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>31.43M</td>
<td>31.76M</td>
<td>29.61M</td>
<td>30.03M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Heron Therapeutics <a href="https://www.benzinga.com/quote/HRTX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Heron Therapeutics: Q4 Earnings Insights

Financial Guidance for 2024
The Company reaffirms its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Product Revenues, Net</td>
<td colspan="1" rowspan="1">$138.0&nbsp;to&nbsp;$158.0 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Operating Expenses (Excluding Stock-Based Compensation and Depreciation and Amortization)</td>
<td colspan="1" rowspan="1">$108.0&nbsp;to&nbsp;$116.0 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (Excluding Stock-Based Compensation and Depreciation and Amortization)</td>
<td colspan="1" rowspan="1">$(22.0)&nbsp;to&nbsp;$3.0 million</td>
</tr>
</tbody>
</table>
</figure>

Heron Therapeutics Sees FY24 Revenue $138M-$158M

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.16) by 56.25 percent.

Earnings Beats

Heron Therapeutics Q4 2023 Adj EPS $(0.07) Beats $(0.16) Estimate

Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-12. Here's what investors need to know before the announcement.
Analysts estimate that Heron Therapeutics will report an earnings per share (EPS) of $-0.16. 
Heron Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.12, which was followed by a 59.26% increase in the share price the next day.
Here's a look at Heron Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.23</td>
<td>-0.20</td>
<td>-0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.35</td>
<td>-0.27</td>
<td>-0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>59.0%</td>
<td>11.0%</td>
<td>-37.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710169274_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Heron Therapeutics were trading at $2.6 as of March 08. Over the last 52-week period, shares are up 12.17%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/HRTX/earnings">To track all earnings releases for Heron Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Heron Therapeutics's Earnings

The FDA has approved&nbsp;Heron Therapeutics Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) supplemental New Drug Application for Zynrelef (bupivacaine and meloxicam) extended-release solution to&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/n36750728/heron-therapeutics-announces-fda-approval-of-zynrelef-indication-expansion-to-include-additional-o" rel="noreferrer noopener">expand the indication</a>&nbsp;for soft tissue and orthopedic surgical procedures, including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.
Zynrelef was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
This expanded indication for Zynrelef will now cover an estimated 13 million procedures annually, an estimated increase of 86% over prior indicated procedures.&nbsp;
To obtain this labeling expansion, Heron conducted studies for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.&nbsp;
No unique safety issues were identified from the new clinical trials, and the bupivacaine and meloxicam blood concentrations were consistent with previous experience following Zynrelef administration.
&#8220;The new label expansion and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/n36526608/heron-therapeutics-announces-partnership-with-crosslink-life-sciences-to-expand-promotional-effort" rel="noreferrer noopener">recent partnership</a>&nbsp;with CrossLink, combined with the potential approval of the Vial Access Needle (&#8220;VAN&#8221;) later this year, are expected to have a significant positive impact for Zynrelef and the Company,&#8221; said Craig Collard, Chief Executive Officer of Heron.
Zynrelef is the first and only therapy for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine solution, the current standard-of-care.&nbsp;
Zynrelef demonstrated superiority compared to bupivacaine, with lower pain scores, fewer patients experiencing severe pain, and lower opioid consumption.&nbsp;
Zynrelef was initially approved by the FDA in May 2021 and received approval of the first supplemental NDA for an&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/12/24528178/fda-approves-indication-expansion-for-heron-therapeutics-post-op-pain-med" rel="noreferrer noopener">expanded label in December 2021</a>.
Price Action:&nbsp;HRTX shares are up 5.91% at $2.33 on the last check Wednesday.

Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod

Heron Therapeutics shares are trading higher after the company announced the FDA approved its supplemental NDA for ZYNRELEF extended-release solution to expand the indication to include additional orthopedic and soft tissue procedures.

Heron Therapeutics Receives FDA Approval Of ZYNRELEF® Indication Expansion To Include Additional Orthopedic And Soft Tissue Procedures

Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>), a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with CrossLink Life Sciences, LLC to expand the sales network supporting ZYNRELEF&reg;&nbsp;(bupivacaine and meloxicam) extended-release solution.
The partnership will launch in several phases, initially at a regional level, followed by an expanded national rollout. In total, approximately 650 representatives will be added to Heron&#39;s sales network over the next year. CrossLink will be the lead partner in&nbsp;the United States&nbsp;to expand ZYNRELEF promotion for orthopedic indications. Under the terms of the agreement, CrossLink is compensated on a fixed-fee per vial basis, based on growth over a pre-determined baseline period

Contracts

Heron Therapeutics Announced Five-Year Distribution Partnership With CrossLink Life Sciences To Expand Promotional Effort for ZYNRELEF

<h3>Gainers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock moved upwards by 63.0% to $0.88 during Wednesday's regular session. As of 12:31 EST, Heron Therapeutics's stock is trading at a volume of 15.8 million, which is 750.5% of its average full-day volume over the last 100 days. The company's market cap stands at $123.8 million. The company's, Q3 earnings came out yesterday. </li>
<li>Kinnate Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNTE#NASDAQ">KNTE</a>) shares increased by 57.32% to $2.47. The current volume of 55.3 million shares is 35889.2% of Kinnate Biopharma's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $116.3 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 34.5% to $2.3. As of 12:31 EST, this security is trading at a volume of 913.3K shares, making up 1243.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $33.9 million. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) stock moved upwards by 33.54% to $4.18. As of 12:31 EST, Cormedix's stock is trading at a volume of 6.3 million, which is 1245.5% of its average full-day volume over the last 100 days. The company's market cap stands at $229.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) shares rose 30.09% to $0.81. Trading volume for this security as of 12:31 EST is 1.7 million, which is 87.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $182.5 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) shares increased by 27.21% to $0.44. As of 12:31 EST, Evelo Biosciences's stock is trading at a volume of 2.9 million, which is 702.9% of its average full-day volume over the last 100 days. The company's market cap stands at $8.3 million. The company's, Q3 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock fell 22.1% to $2.29 during Wednesday's regular session. Trading volume for Aytu BioPharma's stock is 217.6K as of 12:31 EST. This is 138.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock declined by 17.74% to $1.79. Tivic Health Systems's stock is trading at a volume of 541.0K shares as of 12:31 EST. This is 34.4% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock decreased by 16.92% to $0.89. BioCardia's stock is trading at a volume of 5.7 million shares as of 12:31 EST. This is 265.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock declined by 12.84% to $0.28. Trading volume for TransCode Therapeutics's stock is 1.5 million as of 12:31 EST. This is 26.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.5 million. </li>
<li>Homology Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIXX#NASDAQ">FIXX</a>) shares declined by 12.75% to $0.89. As of 12:31 EST, Homology Medicines's stock is trading at a volume of 561.5K, which is 364.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) stock declined by 11.5% to $2.31. The company's market cap stands at $31.6 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYTU

BCDA

CRMD

EVLO

FIXX

GOSS

INTS

KNTE

MIRA

RNAZ

TIVC

<h3>Gainers</h3>
<ul>
<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) shares moved upwards by 65.6% to $1.01 during Wednesday's pre-market session. The market value of their outstanding shares is at $11.3 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock moved upwards by 41.85% to $0.26. The company's market cap stands at $2.7 million. </li>
<li>Kinnate Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNTE#NASDAQ">KNTE</a>) shares increased by 35.66% to $2.13. The market value of their outstanding shares is at $100.3 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock moved upwards by 25.92% to $0.68. The market value of their outstanding shares is at $95.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock rose 25.35% to $2.67. The company's market cap stands at $53.8 million. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares rose 21.72% to $3.81. The company's market cap stands at $208.8 million. The company's, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Graphite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPH#NASDAQ">GRPH</a>) stock fell 14.6% to $1.99 during Wednesday's pre-market session. The company's market cap stands at $115.3 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares decreased by 11.54% to $1.15. The company's market cap stands at $3.5 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock decreased by 11.12% to $0.2. The company's market cap stands at $8.2 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock declined by 10.1% to $1.96. The market value of their outstanding shares is at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares fell 9.94% to $4.35. The market value of their outstanding shares is at $1.9 million. </li>
<li>Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) stock decreased by 9.64% to $17.54. The market value of their outstanding shares is at $708.6 million. As per the news, the Q4 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

GRPH

GTBP

HSCS

SILO

SLDB

VREX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

These Healthcare stocks are trading higher:-Heron Therapeutics Inc (HRTX) stock is trading at $3.10, an increase of $0.74, or 31.36%, on high volume.  Heron Therapeutics gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $6.67.

Healthcare Stocks Moving Up and Down Wednesday: HRTX, ELOX, CRDF, CUE, TNON, TSVT, WORX, ADCT

The market has been high on Heron Therapeutics Inc (HRTX)  stock recently. HRTX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Heron Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on HRTX!See Full HRTX ReportWhat is Stock Sentiment

What is the Market's View on Heron Therapeutics Inc (HRTX) Stock's Price and Volume Trends Thursday?

A rating of 92 puts Heron Therapeutics Inc (HRTX) near the top of the Biotechnology industry according to InvestorsObserver. Heron Therapeutics Inc's score of 92 means it scores higher than 92% of stocks in the industry. Heron Therapeutics Inc also received an overall rating of 78, putting it above 78% of all stocks. Biote

Is Heron Therapeutics Inc (HRTX) a Leader in the Biotechnology Industry?

Heron Therapeutics Inc (HRTX) is near the top in its sector according to InvestorsObserver.HRTX gets an overall rating of 73. That means it scores higher than 73% of stocks.Heron Therapeutics Inc gets a 98 rank in the Healthcare sector. Healthcare is number 2 out of 11 sectors. HRTX has an Overall Score of 73. Find out wha

Will Heron Therapeutics Inc (HRTX) Beat the Rest of the Stocks in the Healthcare Sector?

Heron Therapeutics (HRTX) has issued an update. Ira Duarte has been appointed as the new principal accounting officer of Heron Therapeutics, Inc., ...

Heron Therapeutics Announces New Principal Accounting Officer

The 85 rating InvestorsObserver gives to Heron Therapeutics Inc (HRTX)  stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 96 percent of stocks in the Biotechnology industry, HRTXâ€&#x2122;s 85 overall rating means the stock scores better than 85 percent of all stocks. HRTX has an Overall S

Does Heron Therapeutics Inc (HRTX) Have What it Takes to be in Your Portfolio Monday?

Overall market sentiment has been down on Heron Therapeutics Inc (HRTX)  stock lately. HRTX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. Heron Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on HRTX!See Full HRTX ReportWhat i

Heron Therapeutics Inc (HRTX) Stock: What Does the Chart Say Tuesday?

Heron Therapeutics Inc (HRTX) stock has gained 67.70% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives HRTX stock a score of  80 out of a possible 100. That rank is  influenced by a long-term technical score of 83. HRTX's rank a

Should You Sell Heron Therapeutics Inc (HRTX) Stock Wednesday?

Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics (HRTX – Research Report) today and set a price target of $5.00. Serge ...

Heron Therapeutics: A Strong Buy Based on Strategic Positioning and Growth Potential

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

ADCT

ELOX

TSVT

WORX

Biotech Finds Mid-Week Success Following Q4 Earnings Release

Small Cap

Press Releases

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Heron Therapeutics Stock (NASDAQ:HRTX), Short Interest Report

People Also Watch